In this study, we found that high NRF2 expression was significantly associated with better DFS, DSS, and OS in ER-positive/HER2-negative, but not in other subtypes across two large breast cancer patient cohorts (METABRIC and GSE96058). Here, NFE2L2 is linked to breast carcinoma.